Search results for "Topic"

showing 10 items of 2844 documents

The spectrum of allergic (cross-)sensitivity in clinical patch testing with 'para amino' compounds

2002

Background: Allergic contact sensitization to ‘para amino’ compounds is frequent and the spectrum of cross-reactivity between members of this chemical group is variable. Methods: A retrospective analysis of clinical patch test data obtained with a special test series in the centres of the Information Network of Departments of Dermatology (IVDK) between 1995 and 1999. Results: In the 638 patients tested with the above test panel positive reactions were observed most often to p-aminoazobenzene (16.2%), p-phenylenediamine (14.1%), p-toluylenediamine (10.0%), followed by 4,4′-diaminodiphenylmethane (8.5%), Disperse Orange 3 (8.4%) and p-aminophenol (3.1%). Among the 544 patients tested with p-p…

medicine.medical_specialtyAllergyConcordanceCross sensitivityStatistics as TopicImmunologyCross ReactionsPhenylenediaminesAminophenolsmedicine.disease_causeCross-reactivity030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundSulfanilamide0302 clinical medicineGermanySulfanilamidesmedicineHumansImmunology and AllergyAminesRetrospective Studiesbusiness.industryPatch testp-PhenylenediamineAllergensPatch Testsmedicine.diseaseDermatology3. Good healthchemistryP-Aminoazobenzenep-Aminoazobenzene030220 oncology & carcinogenesisDermatitis Allergic ContactImmunologybusiness4-Aminobenzoic AcidContact dermatitisAllergy
researchProduct

Current management of atopic dermatitis and interruption of the atopic march.

2003

Treatment of atopic dermatitis requires a comprehensive approach that includes evaluation of potential triggers and education of the patient and family regarding proper avoidance measures. Hydration of the skin and maintenance of an intact skin barrier remain integral to proper management. Although topical corticosteroids have been a mainstay of anti-inflammatory therapy, the newer topical calcineurin inhibitors offer advantages for treatment of this chronic, relapsing disease. Studies aimed at defining optimal combination therapy and early intervention might change the treatment paradigm for atopic dermatitis.

medicine.medical_specialtyAllergyImmunologyCalcineurin InhibitorsAnti-Inflammatory AgentsDiseaseEczema Area and Severity IndexDermatitis AtopicAtopyPrevalenceImmunology and AllergyMedicineHumansSCORADAsthmamedicine.diagnostic_testbusiness.industryCalcineurinDisease ManagementAtopic dermatitismedicine.diseaseSkin CareDermatologyAsthmabody regionsCalcineurinDisease ProgressionDermatologic AgentsbusinessThe Journal of allergy and clinical immunology
researchProduct

Is there a role for antileukotrienes in urticaria?

2006

In vitro and in vivo clinical and experimental data have suggested that leukotrienes play a key role in inflammatory reactions of the skin. Antileukotriene drugs, i.e. leukotriene receptor antagonists and synthesis inhibitors, are a new class of anti-inflammatory drugs that have shown clinical efficacy in the management of asthma. We searched the MedLine database and carried out a manual search on journals specializing in allergy and dermatology for the use of antileukotriene drugs in urticaria. Montelukast might be effective in chronic urticaria associated with aspirin or food additive hypersensitivity or with autoreactivity to intradermal serum injection when taken with an antihistamine b…

medicine.medical_specialtyAllergyLeukotrienesSettore MED/09 - Medicina InternaUrticariamedicine.medical_treatmentDermatologyCold urticariaimmune system diseasesparasitic diseasesmedicineHumansZafirlukastskin and connective tissue diseasesMontelukastAsthmaClinical Trials as TopicAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalZileutonmedicine.diseaseDermatologyAntileukotrieneantileukotrieneantileukotrienes; urticariaHistamine H1 AntagonistsLeukotriene AntagonistsAntihistamineDrug Therapy CombinationFood Additivesbusinessmedicine.drugClinical and experimental dermatology
researchProduct

Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A systematic review and meta-analysis

2010

Background The benefit of sublingual immunotherapy (SLIT) with grass allergens for seasonal allergic rhinitis has been extensively studied, but data on efficacy are still equivocal. Objective To assess the effectiveness of SLIT with grass allergens in the reduction of symptoms and medication in patients with seasonal allergic rhinitis to grass pollen. Methods Computerized bibliographic searches of MEDLINE (1995-2010) were supplemented by hand searches of reference lists. Studies were included if they were double-blind randomized controlled trials (RCTs) comparing SLIT to placebo and if they included patients with history of allergy to grass pollen treated with natural grass pollen extracts.…

medicine.medical_specialtyAllergyMEDLINEImmunologyAdministration SublingualPlaceboPoaceaelaw.inventionSublingual administrationRandomized controlled triallawInternal medicineotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansSublingual immunotherapy rhinitis grass meta-analysisAdverse effectRandomized Controlled Trials as Topicbusiness.industryfood and beveragesRhinitis Allergic Seasonalmedicine.diseaseSlitTreatment OutcomeStrictly standardized mean differenceMeta-analysisImmunologyPollenImmunotherapybusiness
researchProduct

World Health Organization guidelines for cancer pain: a reappraisal

2005

Pain is a prevalent symptom experienced by at least 30% ofpatients undergoing an oncological treatment for metastaticdisease and by more than 70% of advanced cancer patients[1]. In 1986 the World Health Organization [2] published a setof guidelines for cancer pain management based on the three-step analgesic ladder [2]. The main aim of WHO guidelienswas to legitimize the prescribing of strong opioids, arisingfrom evidence of poor management of cancer pain, due toreluctance of health care professionals, institutions, and gov-ernment to use opioids because of fears of addition, toleranceand illegal abuse.Its application is reported to achieve satisfactory pain reliefin up to 90% of patients w…

medicine.medical_specialtyAlternative medicinePain reliefPainWorld Health OrganizationWorld healthAdrenal Cortex HormonesNeoplasmsHealth caremedicineHumansIntensive care medicineHigh rateAnalgesicsMorphinebusiness.industryBreakthrough PainSmall sampleHematologytransdermal fentanylAnalgesics OpioidOncologyOpioidAnesthesiaPractice Guidelines as TopicbusinessCancer painmedicine.drugAnnals of Oncology
researchProduct

Anorexia nervosa and cancer: a protocol for a systematic review and meta-analysis of observational studies

2017

BACKGROUND: Anorexia nervosa is characterized by a severe restriction of caloric intake, low body weight, fear of gaining weight or of becoming fat, and disturbance of body image. Pathogenesis of the disorder may include genetic predisposition, hormonal changes and a combination of environmental, psychosocial, and cultural factors. Cancer is the second leading cause of death worldwide. At present, no systematic reviews and meta-analyses have evaluated the risk of cancer in people with anorexia nervosa. The objective of this study will be to evaluate the association between anorexia nervosa and the risk of developing or dying from cancer. METHODS/DESIGN: This study protocol is part of a syst…

medicine.medical_specialtyAnorexia NervosaEpidemiological studyMedicine (miscellaneous)lcsh:Medicine03 medical and health sciences0302 clinical medicineNeoplasmsEpidemiologymental disordersmedicineProtocolHumans030212 general & internal medicinePsychiatryCancerbusiness.industryIncidencelcsh:REating disorderCancerCáncermedicine.disease3. Good healthMeta-analysisSystematic reviewAnorexia nervosa (differential diagnoses)030220 oncology & carcinogenesisMeta-analysisCohortSystematic reviewbibliometríaObservational studybusinessPsychosocialanorexia nerviosaSystematic Reviews as Topic
researchProduct

Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ?

2009

Summary Background:  Statins have emerged as the global leader in pharmacologic therapy for dyslipidaemia, and rosuvastatin has demonstrated clinical efficacy as well as safety in several clinical trials and postmarketing analyses. Aim:  The present article reviewed the effects of rosuvastatin on the quantity and the quality of low-density lipoproteins (LDL). Methods:  We searched for and reviewed all the available evidence in a systematic way. A literature search (by Medline and Scopus) was performed using the following headings: ‘LDL-cholesterol’, ‘LDL size’, ‘LDL subclasses’, ‘small dense LDL’, ‘apolipoprotein B, apo B’ and ‘rosuvastatin’ up to 11 November 2008. The authors also manually…

medicine.medical_specialtyApolipoprotein BHypercholesterolemia10265 Clinic for Endocrinology and DiabetologyMEDLINE610 Medicine & health2700 General MedicinePharmacotherapyInternal medicineDiabetes mellitusmedicineHumansLDL-cholesterolRosuvastatinClinical significanceRosuvastatin CalciumAgedClinical Trials as TopicSulfonamidesbiologybusiness.industrynutritional and metabolic diseasesCholesterol LDLGeneral Medicinemedicine.diseaseFluorobenzenesPrimary PreventionClinical trialPyrimidinesTreatment OutcomeEndocrinologyCardiovascular Diseasesrosuvastatin LDL-cholesterol type-2 diabetesHMG-CoA reductasebiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessmedicine.drug
researchProduct

Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

2012

As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoproteincholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirme…

medicine.medical_specialtyApolipoprotein BPopulationCombined dyslipidemia cholesterol low-density lipoprotein-cholesterol small dense low-density lipoprotein high-density lipoprotein- cholesterol non-high-density lipoprotein-cholesterolchemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusDrug DiscoveryAnimalsHumansMedicineeducationTriglyceridesApolipoproteins BDyslipidemiasPharmacologyLdl cholesteroleducation.field_of_studybiologyTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLAtherosclerosismedicine.diseaseEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromebusinessDyslipidemiaCurrent Pharmaceutical Design
researchProduct

How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL

2017

Background and aims: The maintenance of clinically recommended levels of low-density lipoprotein cholesterol (LDL-C) through a statin therapy is a gold standard in the management of patients with dyslipidaemia and cardiovascular disease (CVD). However, even when LDL-C levels are at or below clinically recommended target levels, residual cardiovascular (CV) risk still remains. Therefore, assessing lipoproteins beyond LDL-C in managing CV risk is imperative. Methods: A working group of clinical experts have assessed the role of lipoproteins other than LDL-C in identifying the CV risk in patients with dyslipidaemia and CVD and in the management of atherogenic dyslipidaemia associated with a nu…

medicine.medical_specialtyApolipoprotein BType 2 diabetes030204 cardiovascular system & hematologyRisk AssessmentTriglyceride03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoprotein cholesterolRisk FactorsInternal medicinemedicineInternal MedicineHumans030212 general & internal medicineAtherogenic dyslipidaemiaHypolipidemic AgentsbiologyCholesterolbusiness.industryDisease Managementnutritional and metabolic diseasesGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCardiovascular diseaseCardiovascular riskResidual riskNon-high-density lipoprotein cholesterolEndocrinologychemistryCardiovascular DiseasesPractice Guidelines as Topicbiology.proteinlipids (amino acids peptides and proteins)Metabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessmentCardiology and Cardiovascular MedicineApolipoprotein BBiomarkersLipoproteinLipoprotein(a)
researchProduct

Concept and Treatment of Hydrocephalus in the Greco-Roman and Early Arabic Medicine

2007

In the ancient medical literature hydrocephalus was not often described although its existence and symptomatology were well known. Most detailed descriptions of hydrocephalus including the surgical treatment are extant in the encyclopaedic works on medicine of the physicians Oreibasios and Aetios from Amida from the 4th and 6th centuries AD, respectively. Because of their broad scientific interests, this type of physicians, typical for the late Roman empire, were known as philosophy-physicians (iota alpha tau rho o sigma o phi iota sigma tau alpha iota). They defined hydrocephalus in contrast to our present understanding as a fluid collection excluding abscesses visible as a bulging tumour …

medicine.medical_specialtyArabicNeurosurgeryAutopsyGreek WorldVentricular systemRoman WorldNeurosurgical ProceduresHumansMedicineTextbooks as TopicHistory AncientHistory 15th CenturyIntracranial pressureCaput succedaneumbusiness.industryArab WorldInfant NewbornMeningesInfantGeneral Medicinemedicine.diseaseHistory MedievalIntracranial Hemorrhage Traumaticlanguage.human_languageHydrocephalusSurgerySkullmedicine.anatomical_structureNeurologylanguageSurgeryNeurology (clinical)businessHydrocephalusmin - Minimally Invasive Neurosurgery
researchProduct